Garuda - Garba Rujukan Digital

UJI IN-SILICO SENYAWA TURUNAN KURKUMINOID SEBAGAI INHIBITOR BRUTON TYROSINE KINASE PADA LEUKIMIA LIMFOSITIK KRONIS Mulki Irpani, Abdul; Ilham Bintang, Muhamad; Putriyanti, Al-fira; Adinda, Deistha; Japar Sodik, Jajang
Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-ilmu Keperawatan, Analis Kesehatan dan Farmasi Vol. 25 No. 1 (2025): Jurnal Kesehatan Bakti Tunas Husada Volume 25 Nomor 1 Tahun 2025
Publisher : LPPM Universitas Bakti Tunas Husada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36465/jkbth.v25i1.1496

Leukemia is a blood cancer that occurs due to abnormal blood cell growth, especially white blood cells in the bone marrow. Research shows that curcumin is proven to be effective in inhibiting the activity of the NF-κB transcription factor which is often involved in the proliferation of cancer cells. This study aims to determine the potential of natural curcuminoid compounds against specific blood cancers, namely chronic lymphocytic leukemia. Through in-silico testing of curcuminoid derivative compounds against the Bruton Tyrosine Kinase protein target which plays a role in the pathophysiological process of chronic lymphocytic leukemia. The results of docking the test ligand molecule on the Tyrosine-protein kinase BTK enzyme, the native ligand has the lowest binding energy value (ΔG) of -12.04 kcal/mol with an inhibition constant (KI) of 1.49 nM. As a comparison drug, imatinib showed ΔG -11.05 kcal/mol with a KI of 7.88 nM. Test ligands s02, s05, and s08. Ligand s02 showed a ΔG of -9.43 kcal/mol with a KI of 123.19 nM, while s05 had a ΔG of -9.09 kcal/mol with a KI of 218.10 nM. Meanwhile, s08 recorded a ΔG of -9.33 kcal/mol and a KI of 143.83 nM. Although the affinity values of the three test ligands were lower than those of the natural ligands, they had the potential to bind to the target enzyme. Based on the interaction analysis, it was seen that s05 had the potential for competitive inhibition, while s02 and s08 showed lower interaction stability compared to imatinib. This indicates that s05 has the greatest potential as a potential inhibitor of the BTK enzyme compared to other test ligands.

Artikel Review: Formulasi dan Karakterisasi Sediaan Granul mengandung Bahan Alam Lian, Kevin Efraim; Hermaniati, Dwiana; Novia Adiningsih, Arum; Yayuk Febryanthi, Anggita; Adinda, Deistha; Musdalifah, Siti; Maria Ina Ose Tapowolo, Selviana
Camellia : Clinical, Pharmaceutical, Analytical and Pharmacy Community Journal Vol 4 No 1 (2025): Camellia (Clinical, Pharmaceutical, Analytical, and Pharmacy Community Journal)
Publisher : Universitas Muhammadiyah Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30651/cam.v4i1.26541

Pengembangan sediaan farmasi dalam pengobatan atau pencegahan suatu penyakit menggunakan bahan alam dengan bentuk sediaan granul telah banyak digunakan. Granul merupakan sediaan obat tersendiri, diantaranya granul instan dan granul effervescent. Bahan alam yang diformulasikan untuk dibuat suatu sediaan farmasi harus memenuhi standarisasi untuk menjamin keamanan, khasiat, dan stabilitas sediaan. Review jurnal ini dilakukan untuk memberi informasi terkait standarisasi, formulasi dan evaluasi sediaan granul yang memanfaatkan bahan alam. Metode dilakukan dengan mengkaji literatur nasional dari sumber data terstandar seperti Google scholar, Sinta, PubMed, dan Science Direct dengan acuan publikasi jurnal pada rentang tahun 2014-2024. Berdasarkan review jurnal yang telah dilakukan, disimpulkan bahwa pembuatan granul lebih banyak menggunakan metode granulasi basah dan sediaan granul dibuat dalam bentuk granul effervescent. dari 21 artikel yang dijadikan sumber, sebanyak 18 artikel memenuhi semua syarat dari evaluasi yang dilakukan sedangkan 3 artikel lainnya hanya memenuhi sebagian syarat uji atau parameter yang dievaluasikan.

Artikel Review: Tanaman yang Memiliki Potensi sebagai Antikanker Payudara Isybillah Ahmad, Afifah; Sulaeman, Agus; Suri Darmawan, Ammar; Yayuk Febriyanthi , Anggita; Novia Adiningsih, Arum; Malik Al Akbar, Ayatullah; Akbar Rulazi, Bagus; Larson Boling Sau, Barth; Adinda, Deistha; Eka Cahyani, Dhiana; Yunita, Dilla; Asherlia, Dwita; Ernawati, Ernawati; Hossanti Ntobu, Febri
Jurnal Medika Farmaka Vol 3 No 1 (2025): Jurnal Medika Farmaka
Publisher : LP4M STIKes Karsa Husada Garut

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33482/jmedfarm.v3i1.58

Introduction: This study examines the role of pharmacotherapy in immune system diseases and cancer, highlighting the potential of natural compounds as anticancer agents. This study reviews various studies using in silico, in vitro, and in vivo approaches to activate the anticancer activity of various plant extracts and bioactive compounds. Method: This article review uses references obtained from database searches with online search instruments published nationally and internationally. Result: The results of the analysis showed that natural compounds contribute to the inhibition of cancer cell growth through apoptosis mechanisms, antioxidant activity, and reduction of inflammation. Various molecular pathways such as HER2, survivin, EGFR, Nrf2-Keap1, and PI3K/AKT/mTOR are the main targets in the development of natural compound-based therapies. The evidence collected shows that natural compounds have great potential as safer and more effective innovative cancer therapies. Conclusion: 13 plants were found to have the potential as anticancer agents in breast cancer therapy, with mechanisms of action including apoptosis induction, inhibition of cancer cell proliferation, modulation of the immune system, and regulation of molecular signaling pathways.

UJI IN-SILICO SENYAWA TURUNAN KURKUMINOID SEBAGAI INHIBITOR BRUTON TYROSINE KINASE PADA LEUKIMIA LIMFOSITIK KRONIS Mulki Irpani, Abdul; Ilham Bintang, Muhamad; Putriyanti, Al-fira; Adinda, Deistha; Japar Sodik, Jajang
Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-ilmu Keperawatan, Analis Kesehatan dan Farmasi Vol 25 No 1 (2025): Jurnal Kesehatan Bakti Tunas Husada Volume 25 Nomor 1 Tahun 2025
Publisher : LPPM Universitas Bakti Tunas Husada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36465/jkbth.v25i1.1496

Leukemia is a blood cancer that occurs due to abnormal blood cell growth, especially white blood cells in the bone marrow. Research shows that curcumin is proven to be effective in inhibiting the activity of the NF-κB transcription factor which is often involved in the proliferation of cancer cells. This study aims to determine the potential of natural curcuminoid compounds against specific blood cancers, namely chronic lymphocytic leukemia. Through in-silico testing of curcuminoid derivative compounds against the Bruton Tyrosine Kinase protein target which plays a role in the pathophysiological process of chronic lymphocytic leukemia. The results of docking the test ligand molecule on the Tyrosine-protein kinase BTK enzyme, the native ligand has the lowest binding energy value (ΔG) of -12.04 kcal/mol with an inhibition constant (KI) of 1.49 nM. As a comparison drug, imatinib showed ΔG -11.05 kcal/mol with a KI of 7.88 nM. Test ligands s02, s05, and s08. Ligand s02 showed a ΔG of -9.43 kcal/mol with a KI of 123.19 nM, while s05 had a ΔG of -9.09 kcal/mol with a KI of 218.10 nM. Meanwhile, s08 recorded a ΔG of -9.33 kcal/mol and a KI of 143.83 nM. Although the affinity values of the three test ligands were lower than those of the natural ligands, they had the potential to bind to the target enzyme. Based on the interaction analysis, it was seen that s05 had the potential for competitive inhibition, while s02 and s08 showed lower interaction stability compared to imatinib. This indicates that s05 has the greatest potential as a potential inhibitor of the BTK enzyme compared to other test ligands.

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search